SecBot SecBot
8-K ·Filed Nov 4, 2026

EW

Edwards Lifesciences Corp
BULLISH
Impact 6/10
Horizonweeks Processed12d 8h ago SEC0001099800-26-000053
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised full-year guidance, strong TMTT growth, and positive clinical/regulatory catalysts (PROGRESS trial, TAVR NCD, new FDA approvals) reinforce the durable growth narrative. Monitor Q4 procedure volume trends and the pace of TAVR market expansion following the NCD update.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$100.82
T+0 close · Nov 4, 2026 · via day close
Latest settled
+4.94%
T+5 · $105.80 · next T+20 in 17d
Vs SPY
+1.65%
α at T+5
Latest observation
+5.96%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $100.82entry
  2. T+1 · 11d ago +1.31%α +1.00% · $102.14
  3. T+5 · 5d ago +4.94%α +1.65% · $105.80
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Edwards Lifesciences reported Q3 2026 adjusted EPS of $0.80, beating the $0.74 consensus by 8.1%, on revenue of $1.72B, above the $1.68B consensus. The company raised full-year 2026 sales growth guidance to approximately 11.5% (from 10-11%), TAVR growth to 9.0-9.5%, and adjusted EPS guidance to $2.97-$3.05. TMTT sales grew 44% YoY to $207M, and the PROGRESS trial data and final TAVR NCD were highlighted as key catalysts.

Key Financial Metrics

EPS (Adj.)
$0.80
est $0.74 · +8.1% · GAAP: $0.53
Revenue
$1.7B
est $1.7B · +2.1% · +10.5% YoY
Rating
beat
Guidance
$6.7B-$6.9B (implied by ~11.5% growth on ~$6.0B base)
raised
Gross Margin
78.5%

Key Facts

  • Q3 2026 sales grew 10.5% to $1.72B, constant currency growth 11.2%
  • Q3 adjusted EPS $0.80, up 19% YoY, beating consensus of $0.74
  • TAVR sales grew 8.0% to $1.24B, constant currency growth 8.8%
  • TMTT sales grew 44.0% to $207M, constant currency growth 45.6%
  • Full-year 2026 sales growth guidance raised to approximately 11.5% from 10-11%
  • Full-year adjusted EPS guidance raised to $2.97-$3.05 from $2.95-$3.05
  • TAVR growth guidance raised to 9.0-9.5% from 8-9%
  • TMTT sales guidance raised to $780-$790M from $760-$780M
  • PROGRESS trial results for moderate AS presented at TCT, published in NEJM
  • CMS released final updated TAVR NCD, expanding access
  • FDA approvals for PASCAL Precision (tricuspid), PASCAL Ace with Capture Clarity, and AUTUS pediatric valve
  • Cash and equivalents $3.1B, total debt $600M
  • Share repurchases of ~$700M YTD, $1.3B remaining under authorization

Financial Impact

Q3 revenue $1.72B vs consensus $1.68B; adjusted EPS $0.80 vs $0.74 consensus; guidance raised across sales, TAVR, TMTT, and EPS

revenueepsguidancesales growth

Segment Breakdown

SegmentRevenueGrowth
TAVR$1.2B+8.0%
TMTT$209.5M+44.3%
Surgical$264.4M+2.5%

Risk Factors

  • TAVR growth deceleration if procedure volume trends soften
  • Currency fluctuations impacting reported results
  • Integration and adoption risks for new product launches (PASCAL, EVOQUE, SAPIEN M3)
  • Potential impact of California R&D tax credit limitation on effective tax rate

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
82% bullish (39 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001099800-26-000053
Document: ew-20261104.htm0001099800-26-000053
Document: 0001099800-26-000053-index-headers.html0001099800-26-000053
Document: 0001099800-26-000053-index.html0001099800-26-000053
Document: 0001099800-26-000053.txt0001099800-26-000053
8-K Data (Synthetic)0001099800-26-000053

Track record

27 reports on EW

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
  2. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
  3. Nov 10, 20266d ago 144 Neutral 2/10 Entry $105.81 Now $107.11 +1.23% settles Nov 18
  4. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
  5. Nov 9, 20267d ago 144 Neutral 3/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $104.01 Now $107.11 +2.98% settles Nov 17
  7. Nov 4, 202612d ago 8-K Bullish 6/10 Viewing Entry $100.82 to $105.80 Now $107.11 +6.24% ▲ +4.94% +1.65% vs SPY
  8. Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $94.44 to $100.82 Now $107.11 +13.42% ▲ +6.76% +11.48% vs SPY
  9. Aug 31, 202611w ago Insider Cluster Neutral 2/10 Entry $90.74 to $86.18 Now $107.11 +18.04% ▼ −5.03% −5.11% vs SPY
  10. Aug 28, 202611w ago Insider Cluster Neutral 2/10 Entry $90.75 to $86.72 Now $107.11 +18.03% ▼ −4.44% −4.30% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 8h 28m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026